Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients

NAActive, not recruitingINTERVENTIONAL
Enrollment

480

Participants

Timeline

Start Date

January 5, 2024

Primary Completion Date

April 3, 2027

Study Completion Date

April 3, 2027

Conditions
Injection Site InfectionSubstance Use Disorders
Interventions
BEHAVIORAL

SIRI Team

"Participants randomized to the intervention will receive integrated ID and SUD care (SIRI Team) both during the hospitalization and after hospital discharge for 4 months post-randomization. The intervention is based upon six general principles for treating PWID with infectious complications and is informed by harm reduction.~1. Medications for SUD as integral to management of infectious complications~2. Integration of ID and SUD care~3. Longitudinal care with familiar providers~4. Multidisciplinary care and care coordination~5. Tailored antibiotic options and care settings~6. Harm reduction"

BEHAVIORAL

Treatment as Usual

Participants assigned to the TAU group will receive the standard treatment for their severe injection-related infection and substance use disorder at each hospital. While TAU may differ between sites, it is typically comprised of a patient being cared for primarily by a hospital medicine physician (hospitalist) with consultation by infectious diseases (ID) and either psychiatry or addiction medicine physician. If the ID or addiction teams believe post-hospitalization follow up is indicated, each service will follow local protocols for arranging post-discharge continuation of care.

Trial Locations (6)

19104

University of Pennsylvania, Philadelphia

33136

University of Miami - Jackson Memorial Hospital, Miami

33601

Tampa General Hospital, Tampa

35294

University of Alabama at Birmingham, Birmingham

84132

University of Utah Hospital, Salt Lake City

87106

University of New Mexico Health Sciences Center, Albuquerque

All Listed Sponsors
collaborator

University of Miami

OTHER

collaborator

Emory University

OTHER

collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

The Emmes Company, LLC

INDUSTRY

lead

Columbia University

OTHER

NCT05688423 - Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients | Biotech Hunter | Biotech Hunter